US Stock MarketDetailed Quotes
AKRO Akero Therapeutics
- 32.730
- +1.530+4.90%
Close Nov 22 16:00 ET
- 32.200
- -0.530-1.62%
Post 20:01 ET
2.28BMarket Cap-8658P/E (TTM)
32.950High31.045Low824.70KVolume31.550Open31.200Pre Close26.63MTurnover1.50%Turnover RatioLossP/E (Static)69.80MShares37.00052wk High3.09P/B1.80BFloat Cap15.32052wk Low--Dividend TTM54.92MShs Float58.380Historical High--Div YieldTTM6.11%Amplitude7.520Historical Low32.287Avg Price1Lot Size
Akero Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -41.64%-70.42M | -156.61%-57.45M | -42.66%-35.14M | -57.12%-145.37M | -90.63%-48.63M | -101.91%-49.72M | -14.76%-22.39M | -7.68%-24.63M | -16.11%-92.52M | 4.45%-25.51M |
| Net income from continuing operations | -83.33%-72.71M | -80.12%-55.99M | -106.51%-53.34M | -35.46%-151.76M | -139.33%-55.19M | -11.58%-39.66M | -13.43%-31.08M | 0.76%-25.83M | -11.17%-112.03M | 28.88%-23.06M |
| Operating gains losses | 6,150.00%125K | 86.11%-10K | 195.06%478K | -74.64%71K | -107.98%-21K | -95.12%2K | -380.00%-72K | 1,900.00%162K | 5,500.00%280K | 122.88%263K |
| Depreciation and amortization | -80.00%1K | -90.91%1K | -90.91%1K | -32.56%29K | -80.00%2K | -54.55%5K | 0.00%11K | 0.00%11K | 4.88%43K | -9.09%10K |
| Other non cash items | 30.29%228K | 616.47%1.22M | -64.78%174K | 142.04%1.02M | 20.81%180K | 17.45%175K | 142.86%170K | 832.08%494K | 107.39%421K | 186.54%149K |
| Change In working capital | 85.81%-1.8M | -233.46%-6.88M | 529.53%13.08M | -49.59%-6.67M | 158.48%3.93M | -1,152.41%-12.71M | 42.45%5.16M | -774.71%-3.04M | -145.84%-4.46M | -363.93%-6.72M |
| -Change in prepaid assets | 21.01%-13.76M | -6,168.42%-8.07M | 562.77%2.34M | -419.13%-6.74M | 2,128.07%11.05M | -3,356.26%-17.42M | 121.88%133K | -118.50%-505K | 200.52%2.11M | -148.32%-545K |
| -Change in payables and accrued expense | 152.11%12.02M | -75.49%1.25M | 531.48%10.8M | 104.73%301K | -15.50%-7.07M | 418.36%4.77M | 19.19%5.1M | 17.37%-2.5M | -153.00%-6.37M | -517.54%-6.12M |
| -Change in other current liabilities | -10.00%-66K | 16.00%-63K | -72.22%-62K | -12.14%-231K | -9.09%-60K | -15.38%-60K | -50.00%-75K | 26.53%-36K | -13.19%-206K | -14.58%-55K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -41.64%-70.42M | -156.61%-57.45M | -42.66%-35.14M | -57.12%-145.37M | -90.63%-48.63M | -101.91%-49.72M | -14.76%-22.39M | -7.68%-24.63M | -16.11%-92.52M | 4.45%-25.51M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 158.13%73.07M | -99.45%-255.9M | 228.87%57.85M | -250.37%-223.62M | 112.60%12.79M | -4,289.90%-125.7M | -1,180.89%-128.3M | -22.68%17.59M | -250.96%-63.83M | -945.38%-101.45M |
| Net intangibles purchase and sale | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net investment purchase and sale | 158.13%73.07M | -98.67%-254.9M | 228.87%57.85M | -250.37%-223.62M | 112.60%12.79M | -4,289.90%-125.7M | -1,180.89%-128.3M | -22.68%17.59M | -250.96%-63.83M | -945.38%-101.45M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 158.13%73.07M | -99.45%-255.9M | 228.87%57.85M | -250.37%-223.62M | 112.60%12.79M | -4,289.90%-125.7M | -1,180.89%-128.3M | -22.68%17.59M | -250.96%-63.83M | -945.38%-101.45M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 280.52%3.07M | -100.04%-150K | 2,321.55%366.94M | 38.21%353.32M | -81.56%502K | -99.63%806K | 865.84%336.86M | 11,379.55%15.15M | 42,363.79%255.63M | 1,020.58%2.72M |
| Net issuance payments of debt | --0 | --0 | -33.33%10M | 50.00%15M | --0 | --0 | --0 | --15M | --10M | --0 |
| Net common stock issuance | --0 | --0 | --355.44M | 39.07%335.43M | --0 | --0 | --335.43M | --0 | --241.2M | --0 |
| Proceeds from stock option exercised by employees | 288.46%3.13M | -82.49%327K | 287.94%1.77M | -30.83%3.66M | -81.55%533K | -61.29%806K | 949.44%1.87M | 210.20%456K | 371.59%5.3M | 962.13%2.89M |
| Net other financing activities | ---64K | -7.92%-477K | 9.57%-274K | 10.19%-776K | 81.33%-31K | --0 | -46.84%-442K | -1,920.00%-303K | -65.83%-864K | -472.41%-166K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 280.52%3.07M | -100.04%-150K | 2,321.55%366.94M | 38.21%353.32M | -81.56%502K | -99.63%806K | 865.84%336.86M | 11,379.55%15.15M | 42,363.79%255.63M | 1,020.58%2.72M |
| Net cash flow | ||||||||||
| Beginning cash position | -30.12%310.36M | 141.81%623.85M | -6.27%234.21M | 65.93%249.88M | -27.95%269.55M | 149.76%444.16M | 71.31%257.99M | 65.93%249.88M | -19.64%150.59M | 126.67%374.11M |
| Current changes in cash | 103.27%5.71M | -268.40%-313.5M | 4,703.93%389.65M | -115.79%-15.67M | 71.55%-35.34M | -188.96%-174.61M | 583.47%186.16M | 135,083.33%8.11M | 369.82%99.29M | -759.60%-124.23M |
| End cash Position | 17.26%316.07M | -30.12%310.36M | 141.81%623.85M | -6.27%234.21M | -6.27%234.21M | -27.95%269.55M | 149.76%444.16M | 71.31%257.99M | 65.93%249.88M | 65.93%249.88M |
| Free cash flow | -41.64%-70.42M | -161.07%-58.45M | -42.66%-35.14M | -57.12%-145.37M | -90.63%-48.63M | -101.91%-49.72M | -14.76%-22.39M | -7.68%-24.63M | -16.11%-92.52M | 4.45%-25.51M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data